Prima BioMed achievs US patent for CVac technology

THE ROADHOUSE PHARMACY: Prima BioMed (ASX: PRR) has received a Notice of Allowance from the United States Patent and Trademark Office, protecting the company’s CVac™ technology.

The company said CVac™ technology is currently in development for ovarian and pancreatic cancer.

“The allowance of this key USA patent is a significant milestone,” Prima BioMed chief executive officer Matthew Lehman said in the company’s announcement to the Australian Securities Exchange.

“The grant of the USA patent would complete the granting of all pending applications relating to the company’s intellectual property portfolio.”

The application protects the method of composition and method of use of Prima’s CVac for the generation of a cytotoxic T cell response against the mucin 1 antigen.

Prima BioMed explained CVac is a personalised immunotherapy composed of a patients’ own dendritic cells pulsed with the cancer antigen mucin 1, conjugated to oxidised mannan fusion protein.

The pulsed dendritic cells are then reinjected into the patient to stimulate an immune response to the mucin 1 cancer antigen.

Website: www.primabiomed.com.au